View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Research Reports
October 13, 2017

GlobalData reports strong growth in monoclonal antibodies during clinical trials from 2007-2016

As part of our series of white papers tracking clinical trials activity across the world, GlobalData recently compiled a summary of global clinical trials in monoclonal antibodies (mAb).

As part of our series of white papers tracking clinical trials activity across the world, GlobalData recently compiled a summary of global clinical trials in monoclonal antibodies (mAb). GlobalData identified 5,273 industry clinical trials with a start date between January 1, 2007, and December 31, 2016. The total number of new clinical trials grew by 115% over the 10-year period; the most prominent increase, 26%, occurred in 2015.

In the report, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively. Overall, Phase II trials outnumbered all other trials by contributing between 31% and 46% across the period. The share of Phase I trials started at 18% in 2007 and increased to 27% by 2016, as shown in Figure. Phase III trials’ contribution remained flat at an average of 24% across the 10-year period, whereas Phase IV trials decreased in share from 13% to 12% in the first and last years, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena